Table 1 Characteristics and demographic data of patients with idiopathic inflammatory myopathies and healthy controls

Number

43

39

22

77

Gender, female/male

35/8

25/14

20/2

58/19

Age, years

58 (41 to 63)

55 (36 to 60)

64 (59 to 70)

45 (31 to 54)

S100A4, ng/ml

26.7 (11.3 to 47.5)

41.6 (24.2 to 123.1)

28.8 (12.6 to 45.4)

23.8 (14.5 to 33.7)

S100A4, ng/ml in females

26.7 (9.0 to 54.7)

54.2 (25.4 to 115.6)

28.8 (13.0 to 47.5)

22.2 (13.6 to 32.1)

S100A4, ng/ml in males

30.3 (19.5 to 44.8)

41.3 (23.9 to 157.9)

20.3 (5.5 to 35.0)

32.3 (19.9 to 64.6)*

Disease duration, years

2.4 (0.4 to 8.3)

0.9 (0.5 to 3.2)

0.6 (0.2 to 3.6)

NA

Biochemical markers

CRP, mg/L

3.3 (1.3 to 9.0)

4.7 (2.2 to 26.1)

8.0 (3.2 to 26.6)

NA

CK, ukat/L

2.6 (1.2 to 9.9)

11.6 (2.0 to 29.3)

10.9 (1.5 to 37.1)

NA

LD, ukat/L

4.4 (3.5 to 6.4)

7.1 (4.2 to 10.9)

5.2 (2.9 to 6.0)

NA

Autoantibodies

6*Mi-2

12*Jo-1;

11*TIF1

NA

4*TIF1, 1*TIF1 + U1RNP

1* Jo-1 + U1RNP;

4*Mi-2

2*NXP2

1*Jo-1 + RNAPI + RNAPII

2*Jo-1, 1*Jo-1 + Ro

3*PM-Scl

2*PM-Scl

1*SAE

3*Jo-1

1*PL7

3*without known aAbs

19*without known aAbs

1*Ku

1*SRP

1*TIF1 + AMA

15*without known aAbs

Clinical features, number

Muscle weakness

43

39

22

NA

Rash

42

1

16

NA

Mechanic's hands

18

10

8

NA

Raynaud's phenomenon

9

10

3

NA

Arthritis

14

14

4

NA

Interstitial lung disease

15

22

5

NA

Cardiac involvement

10

6

3

NA

Dysphagia

21

15

10

NA

Disease activity

MYOACT

0.6 (0.15 to 1.5)

0.7 (0.2 to 1.3)

0.8 (0.5 to 1.8)

NA

Constitutional DA, VAS

6 (0 to 18)

8 (0 to 24)

0 (0 to 28.5)

NA

Cutaneous DA, VAS)

15 (0 to 30)

0 (0 to 6)

28.5 (0 to 52.8)

NA

Skeletal DA, VAS

0 (0 to 0)

0 (0 to 7)

0 (0 to 2)

NA

Gastrointestinal DA, VAS

0 (0 to 4)

0 (0to3)

0 (0 to 25.5)

NA

Pulmonary DA, VAS

0 (0 to 7)

6.5 (0 to 24.7)

0 (0 to 13)

NA

Cardiac DA, VAS

0 (0 to 0)

0 (0 to 0)

0 (0 to 0)

NA

Extramuscular DA, VAS

15 (4 to 34)

17 (3.5 to 32.5)

20 (11.5 to 54.5)

NA

Muscle DA, VAS

10 (3 to 44)

32 (14 to 53)

37 (5.5 to 68.3)

NA

Physician's global disease Assessment, VAS

19.5 (4.5 to 43.7)

30.5 (22.5 to 49.3)

42.5 (13.5 to 52)

NA

HAQ

1.0 (0.3 to 1.9)

0.9 (0.5 to 1.3)

1.0 (0.5 to 2.6)

NA

MMT8

62 (52 to 74)

71 (63 to 74.5)

56 (50.5 to 69.0)

NA

Treatment

Treatment duration, months

13.6 (0.9 to 83.6)

2.0 (0.3 to 72.1)

1.4 (0.0 to 20.6)

NA

Daily glucocorticoid dosage, mg prednisone equivalent

10.0 (2.5 to 40.0)

25.0 (3.8 to 50.0)

6.3 (0.0 to 42.5)

NA

Immunosuppressive drugs

11*MTX, 3*Plaquenil, 2* AZA, 2*CyA, 23*no immunosuppressive drugs at the time of blood withdrawal, 2*before start of the immunosuppressive treatment

10*MTX,1*MTX + AZA, 1*MTX + SAS, 4*CyA, 2*Plaquenil, 1*AZA, 15*no immunosuppressive drugs at the time of blood withdrawal, 5*before start of the immunosuppressive treatment

4*MTX, 11*no immunosuppressive drugs at the time of blood withdrawal, 7*before start of the immunosuppressive treatment

NA